

Fund Details

Base Currency	USD
Inception Date	02 September 2022
Domicile	Ireland
Net Assets	USD 6.5M
Shares Outstanding	310,000
Total Expense Ratio	0.35%
Product Structure	Physical (Full Replication)
UCITS Compliant	Yes
Rebalance Frequency	Semi-Annually
Distribution Frequency	None
Income Treatment	Reinvestment
Swiss Valor	121031038
ISA Eligibility	Yes
SIPP Available	Yes
Countries of Registration	AT, CH, DE, DK, ES, FI, FR, IE, IT, LU, NL, NO, PL, PT, SE, UK

Index Information

Index Provider	MarketVector Indexes
Index Type	Total Return Net
Currency	USD
Inception Date	06 Dec 2021
Rebalance Frequency	Semi-Annually
Bloomberg Ticker	MVFNCTR
Reuters Ticker	.MVFNCTR

Fund Data

Number of Holdings	55
Price/Earnings Ratio*	16.15
Price/Book Ratio*	4.00
Weighted Avg. MCap	USD 32.2B

* Last 12 Months

Country Breakdown

United States	81.06%
China	5.96%
Germany	4.86%
Japan	3.23%
United Kingdom	1.57%
Switzerland	1.16%
Other/Cash	2.16%

➤ www.vaneck.com/ucits/

Fund Description

The VanEck Genomics and Healthcare Innovators UCITS ETF (CURE) is a UCITS-compliant exchange-traded fund that invests in a portfolio of equity securities with the aim of providing investment returns that closely track the performance of the MVIS® Global Future Healthcare ESG Index.

The MVIS® Global Future Healthcare ESG Index is a global index that tracks the performance of companies that are involved in the genomic health care and electronic healthcare industries.

Performance History* (%)

Month End as of 30 Apr 2023	1 MO*	3 MO*	YTD*	1 YR	3 YR	5 YR	10 YR	INCEPTION	ETF
MVFNCTR (Index)	-1.62	-4.00	-0.22	0.07	--	--	--	3.95	

Performance quoted represents past performance. Current performance may be lower or higher than average annual returns shown. Discrete performance shows 12 month performance to the most recent Quarter end for each of the last 5yrs where available. E.g. '1st year' shows the most recent of these 12-month periods and '2nd year' shows the previous 12 month period and so on.

Performance data for VanEck ETFs is displayed on a Net Asset Value basis, in Base Currency terms, with net income reinvested, net of fees. Brokerage or transaction fees will apply.

Top 10 Holdings

VERTEX PHARMACEUTICALS INC	9.35%
REGENERON PHARMACEUTICALS INC	8.42%
DEXCOM INC	6.85%
MODERNA INC	6.41%
ILLUMINA INC	5.80%
VEEVA SYSTEMS INC	5.58%
ALNYLAM PHARMACEUTICALS INC	4.61%
BIONTECH SE	4.24%
INSULET CORP	3.99%
SAREPTA THERAPEUTICS INC	3.26%
SUBTOTAL - TOP 10	58.49%
REMAINING HOLDINGS	41.44%
OTHER/CASH	0.07%
TOTAL	100.00%

For a complete up-to-date listing of Fund holdings, please visit www.vaneck.com

Trading Information

30 April 2023

EXCHANGE	TRADING CURRENCY	ISIN	EXCHANGE TICKER	BLOOMBERG TICKER	REUTERS TICKER	SEDOL	IOPV SYMBOL
LONDON STOCK EXCHANGE	USD	IE000B9PQW54	CURE	CURE LN	CURE.L	BQFP700	CUREUSIV
LONDON STOCK EXCHANGE	GBP	IE000B9PQW54	CURG	CURG LN	CURG.L	BQFP711	CUREUSIV
DEUTSCHE BÖRSE	EUR	IE000B9PQW54	CURE	CURE GY	CURE.DE	BNG7JX1	CUREUSIV
SIX SWISS EXCHANGE	CHF	IE000B9PQW54	CURE	CURE SE	CURE.S	BNG7JZ3	CUREUSIV
BORSA ITALIANA	EUR	IE000B9PQW54	CURE	CURE IM	CURE.MI	BNG7JY2	CUREUSIV

Contact us: For more information, call +353 1 485 4989 or visit www.vaneck.com/ucits/

➤ www.vaneck.com/ucits/